Zacks Research Has Pessimistic Outlook of BHC Q2 Earnings

Bausch Health Cos Inc. (NYSE:BHC) – Equities researchers at Zacks Research reduced their Q2 2027 earnings per share estimates for shares of Bausch Health Cos in a note issued to investors on Wednesday, March 11th. Zacks Research analyst Team now expects that the company will post earnings of $0.89 per share for the quarter, down from their previous forecast of $0.96. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos’ FY2028 earnings at $3.36 EPS.

Several other brokerages have also commented on BHC. Raymond James Financial reaffirmed a “market perform” rating on shares of Bausch Health Cos in a research report on Monday, January 26th. Truist Financial upped their price target on shares of Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a research note on Wednesday, January 7th. Weiss Ratings cut shares of Bausch Health Cos from a “hold (c)” rating to a “sell (d+)” rating in a report on Thursday, February 19th. Wall Street Zen downgraded shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a research note on Sunday, February 15th. Finally, Barclays dropped their price objective on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 25th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus target price of $8.33.

Bausch Health Cos Price Performance

Shares of BHC stock opened at $4.97 on Friday. Bausch Health Cos has a fifty-two week low of $4.25 and a fifty-two week high of $8.69. The company has a debt-to-equity ratio of 54.68, a quick ratio of 1.08 and a current ratio of 1.47. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of 11.82 and a beta of 0.37. The stock’s 50-day simple moving average is $6.20 and its 200-day simple moving average is $6.54.

Bausch Health Cos (NYSE:BHC) last announced its earnings results on Wednesday, February 18th. The company reported $1.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.21 by ($0.13). Bausch Health Cos had a net margin of 1.53% and a return on equity of 875.00%. The business had revenue of $2.78 billion for the quarter, compared to analyst estimates of $2.71 billion.

Institutional Trading of Bausch Health Cos

Several large investors have recently made changes to their positions in the business. Tidal Investments LLC increased its stake in shares of Bausch Health Cos by 2.6% in the second quarter. Tidal Investments LLC now owns 50,131 shares of the company’s stock worth $334,000 after acquiring an additional 1,276 shares during the period. Commonwealth Equity Services LLC lifted its position in Bausch Health Cos by 14.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 14,067 shares of the company’s stock valued at $98,000 after purchasing an additional 1,812 shares during the period. CANADA LIFE ASSURANCE Co boosted its holdings in Bausch Health Cos by 2.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company’s stock valued at $690,000 after purchasing an additional 2,552 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock valued at $51,000 after purchasing an additional 3,106 shares during the last quarter. Finally, Squarepoint Ops LLC grew its position in Bausch Health Cos by 4.6% during the 4th quarter. Squarepoint Ops LLC now owns 78,715 shares of the company’s stock worth $547,000 after purchasing an additional 3,495 shares during the period. 78.65% of the stock is owned by hedge funds and other institutional investors.

More Bausch Health Cos News

Here are the key news stories impacting Bausch Health Cos this week:

• Positive Sentiment: Zacks bumped some near‑term/near‑term‑adjacent forecasts — including FY‑2026 (to $3.92 EPS), Q4‑2026 (to $1.10), Q1‑2027 (to $0.82) and Q3‑2027 (to $1.12) — suggesting parts of the company’s near‑term earnings outlook improved. Zacks revisions (summary)
• Neutral Sentiment: Zacks published an FY‑2028 estimate ($3.36 EPS) which provides a longer‑horizon view but is farther out and less likely to move the stock materially in the short term. FY‑2028 estimate
• Negative Sentiment: Zacks trimmed a number of core near‑term forecasts: Q2‑2027 EPS was cut notably (from $0.96 to $0.89) and Zacks reduced its FY‑2027 outlook (to $3.79 from $3.85), along with cuts to several quarterly estimates — a driver of downward earnings expectations and selling pressure. Zacks cuts (summary)
• Negative Sentiment: The Portnoy Law Firm has opened an investigation into Bausch + Lomb Corporation (BLCO) for possible securities fraud; while that probe targets BLCO, market participants may view it as a reputational/legal overhang for companies carrying the Bausch name or related assets, increasing risk sentiment. Bausch + Lomb investigated (GlobeNewswire)

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.